Santarus has the Highest EBITDA Growth in the Pharmaceuticals Industry (SNTS, OMPI, AKRX)Published on Mon, 11/14/2011 - 11:16
By Mallory Stone in Fast Lane, AKRX, OMPI, SNTS, akorn, highest ebitda growth, nasdaq:akrx, nasdaq:ompi, nasdaq:snts, obagi medical products, santarus
Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.
Santarus (NASDAQ:SNTS) is highest with EBITDA growth of 375.6%. Santarus Inc. is a pharmaceutical company focused on acquiring, developing, and commercializing proprietary products for the prevention and treatment of gastrointestinal diseases and disorders. The primary focus of the company is the development and commercialization of next generation proton pump inhibitor- PPI products.
There is potential upside of 108.7% for shares of Santarus based on a current price of $2.81 and an average consensus analyst price target of $5.88. Santarus shares should first meet resistance at the 50-day moving average (MA) of $2.98 and find additional resistance at the 200-day MA of $3.14.
Obagi Medical Products (NASDAQ:OMPI) is next with EBITDA growth of 172.5%. Thus far today, Obagi Medical Products has traded 8,000 shares, vs. average volume of 59,000 shares per day. The stock has outperformed the Dow (0.4% to the Dow's -0.4%) and outperformed the S&P 500 (0.4% to the S&P's -0.7%) during today's trading.
Finishing up the top three is Akorn (NASDAQ:AKRX), with EBITDA growth of 116.1%.
In the past 52 weeks, Akorn share prices have been bracketed by a low of $4.87 and a high of $10.35 and are now at $9.19, 89% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.4% while the 50-day MA has advanced 1.5%.